{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:21:40Z","timestamp":1760548900518},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1097\/ftd.0b013e3181c91fc4","type":"journal-article","created":{"date-parts":[[2010,1,22]],"date-time":"2010-01-22T08:35:39Z","timestamp":1264149339000},"page":"73-78","source":"Crossref","is-referenced-by-count":7,"title":["Mycophenolic Acid Predose Concentrations and Renal Function in a Mouse Model for Progressive Renal Fibrosis"],"prefix":"10.1097","volume":"32","author":[{"given":"Gunnar","family":"Brandhorst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Brehmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darinka T","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolai","family":"Miosge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor W","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/17425255.1.3.505","article-title":"Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability.","volume":"1","author":"Shipkova","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/j.1523-1755.2004.66030.x","article-title":"Mycophenolate therapy of SLE membranous nephropathy.","volume":"66","author":"Spetie","year":"2004","journal-title":"Kidney Int"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/01.tp.0000255680.71816.aa","article-title":"Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of rapamycin, mycophenolate, cyclosporin, azathioprine, and methylprednisolone.","volume":"83","author":"Copeland","year":"2007","journal-title":"Transplantation"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1600-6143.2004.00533.x","article-title":"Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil.","volume":"4","author":"Merville","year":"2004","journal-title":"Am J Transplant"},{"issue":"Suppl 17","key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1399-0012.2006.00597.x","article-title":"Antifibrotic actions of mycophenolic acid.","volume":"20","author":"Morath","year":"2006","journal-title":"Clin Transplant"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.transproceed.2005.01.049","article-title":"Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration.","volume":"37","author":"Waller","year":"2005","journal-title":"Transplant Proc"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2249.2004.02488.x","article-title":"Effects of commonly used immunosuppressants on graft-derived fibroblasts.","volume":"136","author":"Johnsson","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.106.117051","article-title":"In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil.","volume":"321","author":"Roos","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1093\/ndt\/gfm393","article-title":"Treatment targets in renal fibrosis.","volume":"22","author":"Boor","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI31487","article-title":"Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.","volume":"117","author":"Wynn","year":"2007","journal-title":"J Clin Invest"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1681\/ASN.2005050519","article-title":"Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat.","volume":"17","author":"Kondo","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1097\/01.ASN.0000031827.16102.C1","article-title":"Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice.","volume":"13","author":"Yang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.1523-1755.2004.00901.x","article-title":"Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.","volume":"66","author":"Yu","year":"2004","journal-title":"Kidney Int"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1101\/gad.10.23.2981","article-title":"Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome.","volume":"10","author":"Cosgrove","year":"1996","journal-title":"Genes Dev"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1373\/clinchem.2006.074336","article-title":"Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites.","volume":"52","author":"Brandhorst","year":"2006","journal-title":"Clin Chem"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1373\/clinchem.2003.024323","article-title":"Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid.","volume":"50","author":"Streit","year":"2004","journal-title":"Clin Chem"},{"key":"R20-11-20210129","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ki.1984.147","article-title":"Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats.","volume":"26","author":"Raij","year":"1984","journal-title":"Kidney Int"},{"key":"R21-11-20210129","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1046\/j.1523-1755.1998.00164.x","article-title":"Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.","volume":"54","author":"Peters","year":"1998","journal-title":"Kidney Int"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bmj.1.3454.504","article-title":"Hereditary familial congenital haemorrhagic nephritis.","volume":"1","author":"Alport","year":"1927","journal-title":"BMJ"},{"key":"R23-11-20210129","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1681\/ASN.2004100871","article-title":"Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.","volume":"16","author":"Ninichuk","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R24-11-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1523-1755.2000.00140.x","article-title":"Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney.","volume":"58","author":"Badid","year":"2000","journal-title":"Kidney Int"},{"key":"R25-11-20210129","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/ndt\/16.9.1752","article-title":"Mycophenolate mofetil: implications for the treatment of glomerular disease.","volume":"16","author":"Badid","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R26-11-20210129","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1046\/j.1523-1755.1998.00138.x","article-title":"Mycophenolate mofetil attenuates renal injury in the rat remnant kidney.","volume":"54","author":"Fujihara","year":"1998","journal-title":"Kidney Int"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1681\/ASN.V1071542","article-title":"Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals.","volume":"10","author":"Remuzzi","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R28-11-20210129","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1046\/j.1523-1755.1999.055003945.x","article-title":"Mycophenolate mofetil prevents the progressive renal failure induced by 5\/6 renal ablation in rats.","volume":"55","author":"Romero","year":"1999","journal-title":"Kidney Int"},{"key":"R29-11-20210129","doi-asserted-by":"crossref","first-page":"F359","DOI":"10.1152\/ajprenal.00442.2004","article-title":"Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.","volume":"289","author":"Kramer","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF02829510","article-title":"Effects of mycophenolate mofetil on renal interstitial fibrosis after unilateral ureteral obstruction in rats.","volume":"23","author":"Zhang","year":"2003","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"R31-11-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200108000-00001","article-title":"Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion.","volume":"23","author":"Shaw","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R32-11-20210129","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/TP.0b013e3181664e54","article-title":"Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model.","volume":"85","author":"Heller","year":"2008","journal-title":"Transplantation"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181c91fc4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T17:04:13Z","timestamp":1634749453000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201002000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181c91fc4","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}